The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Luis A. Diaz, Richard T. Williams, Jian Wu, Isaac Kinde, J. Randolph Hecht, Jordan Berlin, Benjamin Allen, Ivana Bozic, Johannes G. Reiter, Martin A. Nowak, Kenneth W Kinzler, Kelly S. Oliner, Bert Vogelstein

Research output: Contribution to journalArticle

Abstract

Colorectal tumours that are wild type for KRAS are often sensitive to EGFR blockade, but almost always develop resistance within several months of initiating therapy. The mechanisms underlying this acquired resistance to anti-EGFR antibodies are largely unknown. This situation is in marked contrast to that of small-molecule targeted agents, such as inhibitors of ABL, EGFR, BRAF and MEK, in which mutations in the genes encoding the protein targets render the tumours resistant to the effects of the drugs. The simplest hypothesis to account for the development of resistance to EGFR blockade is that rare cells with KRAS mutations pre-exist at low levels in tumours with ostensibly wild-type KRAS genes. Although this hypothesis would seem readily testable, there is no evidence in pre-clinical models to support it, nor is there data from patients. To test this hypothesis, we determined whether mutant KRAS DNA could be detected in the circulation of 28 patients receiving monotherapy with panitumumab, a therapeutic anti-EGFR antibody. We found that 9 out of 24 (38%) patients whose tumours were initially KRAS wild type developed detectable mutations in KRAS in their sera, three of which developed multiple different KRAS mutations. The appearance of these mutations was very consistent, generally occurring between 5 and 6months following treatment. Mathematical modelling indicated that the mutations were present in expanded subclones before the initiation of panitumumab treatment. These results suggest that the emergence of KRAS mutations is a mediator of acquired resistance to EGFR blockade and that these mutations can be detected in a non-invasive manner. They explain why solid tumours develop resistance to targeted therapies in a highly reproducible fashion.

Original languageEnglish (US)
Pages (from-to)537-540
Number of pages4
JournalNature
Volume486
Issue number7404
DOIs
StatePublished - Jun 28 2012

Fingerprint

Molecular Evolution
Colorectal Neoplasms
Mutation
Anti-Idiotypic Antibodies
Neoplasms
Therapeutics
Mitogen-Activated Protein Kinase Kinases
DNA
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • General

Cite this

Diaz, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., ... Vogelstein, B. (2012). The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature, 486(7404), 537-540. https://doi.org/10.1038/nature11219

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. / Diaz, Luis A.; Williams, Richard T.; Wu, Jian; Kinde, Isaac; Hecht, J. Randolph; Berlin, Jordan; Allen, Benjamin; Bozic, Ivana; Reiter, Johannes G.; Nowak, Martin A.; Kinzler, Kenneth W; Oliner, Kelly S.; Vogelstein, Bert.

In: Nature, Vol. 486, No. 7404, 28.06.2012, p. 537-540.

Research output: Contribution to journalArticle

Diaz, LA, Williams, RT, Wu, J, Kinde, I, Hecht, JR, Berlin, J, Allen, B, Bozic, I, Reiter, JG, Nowak, MA, Kinzler, KW, Oliner, KS & Vogelstein, B 2012, 'The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers', Nature, vol. 486, no. 7404, pp. 537-540. https://doi.org/10.1038/nature11219
Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012 Jun 28;486(7404):537-540. https://doi.org/10.1038/nature11219
Diaz, Luis A. ; Williams, Richard T. ; Wu, Jian ; Kinde, Isaac ; Hecht, J. Randolph ; Berlin, Jordan ; Allen, Benjamin ; Bozic, Ivana ; Reiter, Johannes G. ; Nowak, Martin A. ; Kinzler, Kenneth W ; Oliner, Kelly S. ; Vogelstein, Bert. / The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. In: Nature. 2012 ; Vol. 486, No. 7404. pp. 537-540.
@article{b8c5c56247c24964a9a70b73e375ab77,
title = "The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers",
abstract = "Colorectal tumours that are wild type for KRAS are often sensitive to EGFR blockade, but almost always develop resistance within several months of initiating therapy. The mechanisms underlying this acquired resistance to anti-EGFR antibodies are largely unknown. This situation is in marked contrast to that of small-molecule targeted agents, such as inhibitors of ABL, EGFR, BRAF and MEK, in which mutations in the genes encoding the protein targets render the tumours resistant to the effects of the drugs. The simplest hypothesis to account for the development of resistance to EGFR blockade is that rare cells with KRAS mutations pre-exist at low levels in tumours with ostensibly wild-type KRAS genes. Although this hypothesis would seem readily testable, there is no evidence in pre-clinical models to support it, nor is there data from patients. To test this hypothesis, we determined whether mutant KRAS DNA could be detected in the circulation of 28 patients receiving monotherapy with panitumumab, a therapeutic anti-EGFR antibody. We found that 9 out of 24 (38{\%}) patients whose tumours were initially KRAS wild type developed detectable mutations in KRAS in their sera, three of which developed multiple different KRAS mutations. The appearance of these mutations was very consistent, generally occurring between 5 and 6months following treatment. Mathematical modelling indicated that the mutations were present in expanded subclones before the initiation of panitumumab treatment. These results suggest that the emergence of KRAS mutations is a mediator of acquired resistance to EGFR blockade and that these mutations can be detected in a non-invasive manner. They explain why solid tumours develop resistance to targeted therapies in a highly reproducible fashion.",
author = "Diaz, {Luis A.} and Williams, {Richard T.} and Jian Wu and Isaac Kinde and Hecht, {J. Randolph} and Jordan Berlin and Benjamin Allen and Ivana Bozic and Reiter, {Johannes G.} and Nowak, {Martin A.} and Kinzler, {Kenneth W} and Oliner, {Kelly S.} and Bert Vogelstein",
year = "2012",
month = "6",
day = "28",
doi = "10.1038/nature11219",
language = "English (US)",
volume = "486",
pages = "537--540",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7404",

}

TY - JOUR

T1 - The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

AU - Diaz, Luis A.

AU - Williams, Richard T.

AU - Wu, Jian

AU - Kinde, Isaac

AU - Hecht, J. Randolph

AU - Berlin, Jordan

AU - Allen, Benjamin

AU - Bozic, Ivana

AU - Reiter, Johannes G.

AU - Nowak, Martin A.

AU - Kinzler, Kenneth W

AU - Oliner, Kelly S.

AU - Vogelstein, Bert

PY - 2012/6/28

Y1 - 2012/6/28

N2 - Colorectal tumours that are wild type for KRAS are often sensitive to EGFR blockade, but almost always develop resistance within several months of initiating therapy. The mechanisms underlying this acquired resistance to anti-EGFR antibodies are largely unknown. This situation is in marked contrast to that of small-molecule targeted agents, such as inhibitors of ABL, EGFR, BRAF and MEK, in which mutations in the genes encoding the protein targets render the tumours resistant to the effects of the drugs. The simplest hypothesis to account for the development of resistance to EGFR blockade is that rare cells with KRAS mutations pre-exist at low levels in tumours with ostensibly wild-type KRAS genes. Although this hypothesis would seem readily testable, there is no evidence in pre-clinical models to support it, nor is there data from patients. To test this hypothesis, we determined whether mutant KRAS DNA could be detected in the circulation of 28 patients receiving monotherapy with panitumumab, a therapeutic anti-EGFR antibody. We found that 9 out of 24 (38%) patients whose tumours were initially KRAS wild type developed detectable mutations in KRAS in their sera, three of which developed multiple different KRAS mutations. The appearance of these mutations was very consistent, generally occurring between 5 and 6months following treatment. Mathematical modelling indicated that the mutations were present in expanded subclones before the initiation of panitumumab treatment. These results suggest that the emergence of KRAS mutations is a mediator of acquired resistance to EGFR blockade and that these mutations can be detected in a non-invasive manner. They explain why solid tumours develop resistance to targeted therapies in a highly reproducible fashion.

AB - Colorectal tumours that are wild type for KRAS are often sensitive to EGFR blockade, but almost always develop resistance within several months of initiating therapy. The mechanisms underlying this acquired resistance to anti-EGFR antibodies are largely unknown. This situation is in marked contrast to that of small-molecule targeted agents, such as inhibitors of ABL, EGFR, BRAF and MEK, in which mutations in the genes encoding the protein targets render the tumours resistant to the effects of the drugs. The simplest hypothesis to account for the development of resistance to EGFR blockade is that rare cells with KRAS mutations pre-exist at low levels in tumours with ostensibly wild-type KRAS genes. Although this hypothesis would seem readily testable, there is no evidence in pre-clinical models to support it, nor is there data from patients. To test this hypothesis, we determined whether mutant KRAS DNA could be detected in the circulation of 28 patients receiving monotherapy with panitumumab, a therapeutic anti-EGFR antibody. We found that 9 out of 24 (38%) patients whose tumours were initially KRAS wild type developed detectable mutations in KRAS in their sera, three of which developed multiple different KRAS mutations. The appearance of these mutations was very consistent, generally occurring between 5 and 6months following treatment. Mathematical modelling indicated that the mutations were present in expanded subclones before the initiation of panitumumab treatment. These results suggest that the emergence of KRAS mutations is a mediator of acquired resistance to EGFR blockade and that these mutations can be detected in a non-invasive manner. They explain why solid tumours develop resistance to targeted therapies in a highly reproducible fashion.

UR - http://www.scopus.com/inward/record.url?scp=84863000299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863000299&partnerID=8YFLogxK

U2 - 10.1038/nature11219

DO - 10.1038/nature11219

M3 - Article

C2 - 22722843

AN - SCOPUS:84863000299

VL - 486

SP - 537

EP - 540

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7404

ER -